Kodiak Sciences (NASDAQ:KOD – Get Free Report) and MeiraGTx (NASDAQ:MGTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.
Valuation & Earnings
This table compares Kodiak Sciences and MeiraGTx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kodiak Sciences | N/A | N/A | -$260.49 million | ($3.36) | -0.68 |
| MeiraGTx | $33.28 million | 12.72 | -$84.03 million | ($2.13) | -2.52 |
MeiraGTx has higher revenue and earnings than Kodiak Sciences. MeiraGTx is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Kodiak Sciences | N/A | -84.52% | -45.40% |
| MeiraGTx | -633.05% | -146.38% | -53.05% |
Insider and Institutional Ownership
89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by insiders. Comparatively, 8.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Kodiak Sciences and MeiraGTx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kodiak Sciences | 1 | 1 | 1 | 0 | 2.00 |
| MeiraGTx | 0 | 0 | 2 | 0 | 3.00 |
Kodiak Sciences presently has a consensus target price of $9.00, indicating a potential upside of 291.30%. MeiraGTx has a consensus target price of $24.50, indicating a potential upside of 356.24%. Given MeiraGTx’s stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Kodiak Sciences.
Risk and Volatility
Kodiak Sciences has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
Summary
Kodiak Sciences beats MeiraGTx on 7 of the 13 factors compared between the two stocks.
About Kodiak Sciences
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
